Journal Article
. 2011 Jan;127(1).
doi: 10.1007/s10549-010-1331-z.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Gong Tang 1 Steven Shak  Soonmyung Paik  Stewart J Anderson  Joseph P Costantino  Charles E Geyer  Eleftherios P Mamounas  D Lawrence Wickerham  Norman Wolmark  
Affiliations
  • PMID: 21221771
  •     22 References
  •     67 citations

Abstract

The Oncotype DX Recurrence Score (RS) is a validated genomic predictor of outcome and response to adjuvant chemotherapy in ER-positive breast cancer. Adjuvant! was developed using SEER registry data and results from the Early Breast Cancer Clinical Trialists' overview analyses to estimate outcome and benefit from adjuvant hormonal therapy and chemotherapy. In this report we compare the prognostic and predictive utility of these two tools in node-negative, ER-positive breast cancer. RS and Adjuvant! results were available from 668 tamoxifen-treated NSABP B-14 patients, 227 tamoxifen-treated NSABP B-20 patients, and 424 chemotherapy plus tamoxifen-treated B-20 patients. Adjuvant! results were also available from 1952 B-20 patients. The primary endpoint was distant recurrence-free interval (DRFI). Cox proportional hazards models were used to compare the prognostic and predictive utility of RS and Adjuvant!. Both RS (P < 0.001) and Adjuvant! (P = 0.002) provided strong independent prognostic information in tamoxifen-treated patients. Combining RS and individual clinicopathologic characteristics provided greater prognostic discrimination than combining RS and the composite Adjuvant!. In the B-20 cohort with RS results (n = 651), RS was significantly predictive of chemotherapy benefit (interaction P = 0.031 for DRFI, P = 0.011 for overall survival [OS], P = 0.082 for disease-free survival [DFS]), but Adjuvant! was not (interaction P = 0.99, P = 0.311, and P = 0.357, respectively). However, in the larger B-20 sub-cohort (n = 1952), Adjuvant! was significantly predictive of chemotherapy benefit for OS (interaction P = 0.009) but not for DRFI (P = 0.219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit.

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.
L Assersohn, J Salter, +5 authors, M Dowsett.
Breast Cancer Res Treat, 2003 Dec 25; 82(2). PMID: 14692655
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
B Fisher, J Costantino, +7 authors, E R Fisher.
N Engl J Med, 1989 Feb 23; 320(8). PMID: 2644532
Highly Cited.
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C W Elston, I O Ellis.
Histopathology, 1991 Nov 01; 19(5). PMID: 1757079
Highly Cited.
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
B Fisher, J Dignam, +10 authors, R G Margolese.
J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
R J Burcombe, A Makris, +7 authors, G D Wilson.
Br J Cancer, 2004 Dec 22; 92(1). PMID: 15611798    Free PMC article.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
John A Foekens, David Atkins, +17 authors, Yixin Wang.
J Clin Oncol, 2006 Mar 01; 24(11). PMID: 16505412
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Frédérique Penault-Llorca, Fabrice André, +11 authors, Henri Roché.
J Clin Oncol, 2009 Apr 22; 27(17). PMID: 19380452
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
B Fisher, J Dignam, J Bryant, N Wolmark.
J Natl Cancer Inst, 2001 May 03; 93(9). PMID: 11333290
How much can improved molecular and pathologic discriminants change local therapy?
Monica Morrow.
Breast Cancer Res, 2009 Jan 16; 10 Suppl 4. PMID: 19128443    Free PMC article.
Tailored targeted therapy for all: a realistic and worthwhile objective against.
Kathleen I Pritchard.
Breast Cancer Res, 2010 Jan 20; 11 Suppl 3. PMID: 20030883    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
Impact of multigene assays in early stage breast cancer.
Shelly S Lo, Kathy S Albain.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016475    Free PMC article.
Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform.
M Abramovitz, B G Barwick, +8 authors, B Leyland-Jones.
Br J Cancer, 2011 Nov 10; 105(10). PMID: 22067903    Free PMC article.
Translational genomics: the challenge of developing cancer biomarkers.
James D Brooks.
Genome Res, 2012 Feb 04; 22(2). PMID: 22301132    Free PMC article.
Cancer biomarkers: selecting the right drug for the right patient.
Gary J Kelloff, Caroline C Sigman.
Nat Rev Drug Discov, 2012 Feb 11; 11(3). PMID: 22322254
Highly Cited. Review.
Toward individualized breast cancer therapy: translating biological concepts to the bedside.
Gabriel N Hortobagyi.
Oncologist, 2012 Apr 05; 17(4). PMID: 22474069    Free PMC article.
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
S Barton, L Zabaglo, +6 authors, M Dowsett.
Br J Cancer, 2012 Apr 26; 106(11). PMID: 22531639    Free PMC article.
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.
Lawrence J Solin, Robert Gray, +10 authors, Joseph A Sparano.
Breast Cancer Res Treat, 2012 May 02; 134(2). PMID: 22547108    Free PMC article.
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.
Shelby D Reed, Michaela A Dinan, Kevin A Schulman, Gary H Lyman.
Genet Med, 2012 Sep 15; 15(3). PMID: 22975761    Free PMC article.
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Zsuzsanna Varga, Peter Sinn, +6 authors, Holger Moch.
PLoS One, 2013 Mar 19; 8(3). PMID: 23505515    Free PMC article.
Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT.
Ana María García Vicente, Ángel Soriano Castrejón, +6 authors, Ana González Ageitos.
Eur J Nucl Med Mol Imaging, 2013 May 02; 40(9). PMID: 23632960
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Clara Chen, Rahul Dhanda, +2 authors, Debra A Patt.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942918    Free PMC article.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Takayuki Ueno, Norikazu Masuda, +12 authors, Masakazu Toi.
Int J Clin Oncol, 2013 Oct 09; 19(4). PMID: 24101215
Sleep duration and breast cancer phenotype.
Ali Khawaja, Santosh Rao, Li Li, Cheryl L Thompson.
J Cancer Epidemiol, 2013 Dec 10; 2013. PMID: 24319459    Free PMC article.
Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.
Kimberly Mislick, Warren Schonfeld, Carolyn Bodnar, Kuo Bianchini Tong.
Clinicoecon Outcomes Res, 2014 Jan 29; 6. PMID: 24470765    Free PMC article.
Regional differences in breast cancer biomarkers in american Indian and Alaska native women.
Judith S Kaur, Robert A Vierkant, Timothy Hobday, Daniel Visscher.
Cancer Epidemiol Biomarkers Prev, 2014 Mar 13; 23(3). PMID: 24609850    Free PMC article.
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Bahriye Aktas, Agnes Bankfalvi, +2 authors, Sabine Kasimir-Bauer.
Mol Clin Oncol, 2014 Mar 22; 1(6). PMID: 24649291    Free PMC article.
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.
Alex Farr, Rachel Wuerstlein, +2 authors, Nadia Harbeck.
Rev Obstet Gynecol, 2013 Jan 01; 6(3-4). PMID: 24920978    Free PMC article.
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Hideko Yamauchi, Chizuko Nakagawa, +9 authors, Seigo Nakamura.
BMC Health Serv Res, 2014 Sep 06; 14. PMID: 25190451    Free PMC article.
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
Terri Patricia McVeigh, Lauren M Hughes, +4 authors, Michael J Kerin.
Eur J Cancer, 2014 Sep 23; 50(16). PMID: 25240289    Free PMC article.
Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.
Michael Marrone, Alison Stewart, W David Dotson.
Genet Med, 2014 Dec 05; 17(7). PMID: 25474343    Free PMC article.
Review.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
Biomarker development in the context of urologic cancers.
Gary J Kelloff, Caroline C Sigman, Howard I Scher.
Urol Oncol, 2015 Mar 10; 33(6). PMID: 25746942    Free PMC article.
Review.
Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?
Debarshi Jana, Diptendra Kumar Sarkar, +3 authors, Syamsundar Mandal.
Indian J Surg Oncol, 2015 Mar 15; 5(4). PMID: 25767340    Free PMC article.
[Molecular pathology for breast cancer: Importance of the gene expression profile].
C Denkert, B M Pfitzner, B I Heppner, M Dietel.
Pathologe, 2015 Apr 04; 36(2). PMID: 25836324
Review.
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Elizabeth J Sutton, Jung Hun Oh, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2015 Apr 09; 42(5). PMID: 25850931    Free PMC article.
Highly Cited.
Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result.
Molly Andreason, Chong Zhang, +7 authors, Amye J Tevaarwerk.
J Community Support Oncol, 2015 Jun 02; 13(5). PMID: 26029936    Free PMC article.
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.
J Ribeiro, B Sousa, F Cardoso.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217109    Free PMC article.
Review.
Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs.
Jeanette K Birnbaum, Foluso O Ademuyiwa, +3 authors, Ruth Etzioni.
Med Decis Making, 2015 Aug 26; 36(5). PMID: 26304062    Free PMC article.
Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Maria Karsten, Michelle Stempel, +2 authors, Tari A King.
Ann Surg Oncol, 2015 Sep 06; 23(2). PMID: 26340863    Free PMC article.
Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
Lik Hang Lee, Paul E Swanson, +2 authors, Hua Yang.
Appl Immunohistochem Mol Morphol, 2015 Sep 16; 25(1). PMID: 26371428    Free PMC article.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
J Natl Compr Canc Netw, 2015 Oct 21; 13(10). PMID: 26483061    Free PMC article.
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
Genet Med, 2015 Dec 19; 18(8). PMID: 26681310
The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?
Yadong Sun, Xiaofeng Liu, +8 authors, Jiaxiang Wang.
Tumour Biol, 2016 Jan 23; 37(7). PMID: 26790445
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
Review.
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Josee-Lyne Ethier, Eitan Amir.
Mol Diagn Ther, 2016 May 29; 20(4). PMID: 27235162
Review.
Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Vida Pourteimoor, Samira Mohammadi-Yeganeh, Mahdi Paryan.
Tumour Biol, 2016 Sep 22; 37(11). PMID: 27651157
Review.
A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.
Kristian Jensen, Rikke Krusenstjerna-Hafstrøm, +2 authors, Helene Derand.
Mod Pathol, 2016 Oct 22; 30(2). PMID: 27767098
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Kevin K Dobbin, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 29; 4. PMID: 27891226    Free PMC article.
Review.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Hyun-Seok Kim, Christopher B Umbricht, +22 authors, Leslie Cope.
J Clin Oncol, 2016 Dec 22; 34(36). PMID: 27998227    Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
Maura Bríd Cotter, Alex Dakin, +5 authors, Cecily M Quinn.
Virchows Arch, 2017 Jul 15; 471(3). PMID: 28707056
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss.
Surg Oncol Clin N Am, 2017 Nov 15; 27(1). PMID: 29132568    Free PMC article.
Review.
Molecular Signatures of Radiation Response in Breast Cancer: Towards Personalized Decision-Making in Radiation Treatment.
Corey Speers, Lori J Pierce.
Int J Breast Cancer, 2018 Jan 20; 2017. PMID: 29348942    Free PMC article.
Review.
Investigating a multigene prognostic assay based on significant pathways for Luminal A breast cancer through gene expression profile analysis.
Haiyan Gao, Mei Yang, Xiaolan Zhang.
Oncol Lett, 2018 Mar 17; 15(4). PMID: 29545900    Free PMC article.
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Shi-Yi Wang, Weixiong Dang, +3 authors, Cary P Gross.
J Clin Oncol, 2018 Apr 17; 36(16). PMID: 29659329    Free PMC article.
Systematic Review.
Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.
Robin W Jansen, Paul van Amstel, +10 authors, Marcus C de Jong.
Oncotarget, 2018 May 08; 9(28). PMID: 29732009    Free PMC article.
Review.
Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival.
Andy Evans, Yee Ting Sim, +7 authors, Paul Pharoah.
Breast Cancer Res Treat, 2018 Jun 03; 171(2). PMID: 29858751    Free PMC article.
Patient Similarity Networks for Precision Medicine.
Shraddha Pai, Gary D Bader.
J Mol Biol, 2018 Jun 04; 430(18 Pt A). PMID: 29860027    Free PMC article.
Review.
TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.
Joseph A Sparano, Robert Gray.
J Clin Oncol, 2019 Jun 08; 37(21). PMID: 31173552    Free PMC article.
Research-based PAM50 signature and long-term breast cancer survival.
Minya Pu, Karen Messer, +10 authors, Loki Natarajan.
Breast Cancer Res Treat, 2019 Sep 23; 179(1). PMID: 31542876    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
A blood-based prognostic biomarker in IBD.
Daniele Biasci, James C Lee, +9 authors, Kenneth G C Smith.
Gut, 2019 Apr 29; 68(8). PMID: 31030191    Free PMC article.
Stratification Using hTERT and Stem Cell Markers Confers a Good Prognosis in Invasive Breast Cancer.
Umar Wazir, Salim Tayeh, +3 authors, Kefah Mokbel.
Cancer Genomics Proteomics, 2020 Feb 29; 17(2). PMID: 32108039    Free PMC article.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.
Natalia R Kunst, Fernando Alarid-Escudero, A David Paltiel, Shi-Yi Wang.
Value Health, 2019 Sep 30; 22(10). PMID: 31563252    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
Review.
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.
Alberto Zambelli, Edda Simoncini, +11 authors, Carlo Tondini.
Breast, 2020 Apr 24; 52. PMID: 32325372    Free PMC article.
Prognosis vs Treatment Interaction.
Jack Cuzick.
JNCI Cancer Spectr, 2018 Apr 28; 2(1). PMID: 31360838    Free PMC article.
Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database.
Ran Cheng, Xiangyi Kong, +2 authors, Jing Wang.
Front Oncol, 2020 Nov 17; 10. PMID: 33194568    Free PMC article.